CTXR - Citius Pharmaceuticals, Inc.

0.9486
0.132   13.936%

Share volume: 2,334,779
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$0.82
0.13
0.16%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 4%
Liquidity 43%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
31.20%
1 Month
25.69%
3 Months
-15.30%
6 Months
-22.25%
1 Year
-46.71%
2 Year
32.67%
Key data
Stock price
$0.95
P/E Ratio 
0.00
DAY RANGE
$0.87 - $1.00
EPS 
-$3.17
52 WEEK RANGE
$0.63 - $2.48
52 WEEK CHANGE
-$47.01
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.67
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$672,431
AVERAGE 30 VOLUME 
$641,817
Company detail
CEO: Leonard L. Mazur
Region: US
Website: citiuspharma.com
Employees: 20
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Citius Pharmaceuticals, Inc. engages in the development and commercialization of critical care products. The company is developing five proprietary products, including Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. MinoWrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, and Halo-Lido, a corticosteroid-lidocaine topical formulation.

Recent news